We're ScreenPoint Medical

We are bringing AI to the fight against breast cancer and are looking for passionate, talented people to help us.  Why not join our team?

Improve patient outcomes

We are working with breast clinicians to continually improve the clinically proven deep learning algorithms in Transpara™. We are committed to further improve accuracy, consistency and reduce unnecessary recalls, a common cause of anxiety for women undergoing mammography.

Deep learning
From the leaders in development of deep learning Artificial Intelligence (AI) for mammography and breast imaging picture

40 years experience

From the leaders in development of deep learning Artificial Intelligence (AI) for mammography and breast imaging

Our history

ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, world leading experts in quantitative breast image analysis and computer aided detection.

Read more

Our history

ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, world leading experts in quantitative breast image analysis and computer aided detection.

They have led research projects in the field for over twenty years and have made important contributions to leading breast imaging products. 

Prof Karssemeijer says, “I started ScreenPoint Medical because I wanted my academic work to have a greater impact beyond the publication of scientific papers. I knew our work held out the promise to ultimately improve breast cancer survival rates and recognised the huge potential of my university team to develop a really outstanding product. By using the technological advances of Deep Learning Artificial Intelligence, we have overtaken current CAD systems to produce faster and more accurate results.”



Our technology

The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer.

Read more

Our technology

The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer.

“Transpara is now being used by radiologists in clinical practice, but this is only the beginning! We are constantly innovating and we will continue to help doctors to achieve higher breast cancer survival rates and at the same time, minimise patient distress and the cost of unnecessary treatments.”

“But we always remember that our excellence in innovation must be matched by the way we run our business. We are lean, focused on producing optimum results with cost savings passed on to our customers.”

Co-Founder of ScreenPoint Medical, Sir Michael Brady, was known internationally for his ground-breaking work in robotic image analysis at the University of Oxford but the death of his mother in law from breast cancer, caused him to change direction:

“I wanted to understand why the medical profession wasn’t able to do a better job of detecting breast cancers at an earlier stage when they were more treatable.  So I decided to move away from robotics and concentrate on the analysis of breast scans.’

My colleagues and I developed a mathematical model of the passage of X-rays through female breast tissue, a fundamental step towards developing a system able to recognise potential tumours.

I met Nico Karssemeijer from Nijmegen University in 2000 when he was giving a keynote lecture on parallel research.

Both of us wanted to help radiologists identify potential cancers faster and at an earlier stage and to increase the chances of more women surviving breast cancer.

In 2014 we started ScreenPoint Medical.  We built a superb team of scientists to develop a unique system, Transpara, a blend of classic physics and deep learning artificial intelligence, presented as a decision support tool to increase efficiency.

There are fewer and fewer radiologists specialising in reading mammograms at a time when breast cancer incidence is increasing worldwide.

ScreenPoint are the only people that combine deep understanding of the physics, knowledge of clinical workflow and deep learning AI techniques to improve accuracy and speed of detection. Transpara is the world leader!”



Our team

The Board Members and Executive Team

 picture

Sir Michael  Brady

Chairman - Supervisory Board

View Biog
 picture

Anirudha  Dambal

Supervisory Board Member

View Biog
 picture

Allyson   White

Supervisory Board Member

View Biog
 picture

Dr Rachel  Brem

Supervisory Board Member

View Biog
 picture

Mark   Koeniguer

CEO

View Biog
 picture

Nico  Karssemeijer

CSO

View Biog
 picture

Pieter  Kroese

COO

View Biog
 picture

Albert  Gubern-Mérida

CTO

View Biog
 picture

Sir Michael Brady

Chairman - Supervisory Board

Professor Sir Michael Brady FRS FMedSci FREng is a world leading scientist in computer vision, robotics, and medical image analysis.  He co-authored Mammographic Image Analysis (Kluwer 1999) with Ralph Highnam; the ideas introduced in this monograph – together with some later innovative developments by Nico Karssemeijer and colleagues – provided the basis for Volpara density.  As well, Brady has co-founded and steered several small high-growth technology companies to success.  In addition to Matakina, he is a Founder Director of: Perspectum Diagnostics, Mirada Medical, and Guidance Navigation; as well as being Chairman of:  Acuitas Medical, IRISS Medical, Colwiz,  and was until recently Deputy Chairman of Oxford Instruments plc.

 picture

Anirudha Dambal

Supervisory Board Member

Anirudha has strong cross-functional expertise across general management, strategy, product & innovation management, and sales operations addressing customers across the world. In his function as vice president of New X-ray Markets at Siemens Healthineers, he is responsible for identifying and bringing new business opportunities in the X-ray products business line to the market. In his previous role, he was the head of the global value segment X-ray products where he drove the definition and development of a new mobile C-arm platform. He has also served as the head of CRM and sales analytics and as business manager for South Asia in prior positions. As a non-executive director at ScreenPoint Medical, he is jointly working towards improved breast cancer diagnosis using artificial intelligence.

 picture

Allyson White

Supervisory Board Member

PRINCIPAL, ONSITE

Allyson joined Insight in 2012. Previously, she was a strategy consultant in the markets and customers practice at Monitor Group, where she advised multi-national companies on growth strategy, product innovation, acquisitions, scenario planning and pricing strategy. She worked in a variety of industries including Pharmaceutical, Insurance, and Chemicals.

Allyson graduated with high honors from the Huntsman Program in International Studies and Business at the University of Pennsylvania. She is fluent in Spanish.

 picture

Dr Rachel Brem

Supervisory Board Member

Dr. Rachel Brem is the Director of Breast Imaging and Intervention at The George Washington University Medical Center, Professor of Radiology and the Vice Chairman of the Department of Radiology. In 2015 Dr. Brem was named the Program Leader for Breast Cancer at the GW Cancer Center. Dr. Brem completed her undergraduate studies at Brandeis University followed by medical school at Columbia University where she graduated with honors. Dr. Brem completed both her Diagnostic Radiology Residency and Breast Imaging Fellowship at the John Hopkins Medical Institutions. Since completion of her training Dr. Brem was on the faulty at John Hopkins as the Director of Breast Imaging. Currently she is the Director of Breast Imaging and Interventional Center at the George Washington Medical Institution and Professor of Radiology. Dr. Brem’s research and clinical interest includes Minimally Invasive Breast Biopsy as well as New Technologies for the Earlier Diagnosis of breast cancer focusing Whole Breast Ultrasound for women with dense breast tissue for improved breast cancer detection and risk assessment, Artificial Intelligence for breast cancer detection and Molecular Imaging of the Breast. She currently directs multi-institutional clinical trials evaluating novel approaches to improved diagnosis of breast cancer and is the recipient of numerous honors and awards including Best Cancer Doctors (Newsweek), Castle Connolly Best Doctors for Cancer and Top Doctor, Jewish Woman International’s Ten Women to Watch, the prestigious fellowship in the American College of Radiology and the Society of Breast Imaging. She is an internationally recognized expert on Breast Cancer who is sought to speak on the subject nationally and internationally. Dr. Brem has extensively published, and is also committed to mentoring of students and residents. She is on the scientific advisory board of The Prevent Cancer Foundation as well as FORCE (Facing our risk of cancer, for women who are BR CA positive) and is a member of the Board of the Katzen Cancer Research Center. She currently serves on the Board of Directors of Delphinus Medical Technologies, Dilon Technologies and Screenpoint Medical. Previously she served on the Board of Directors of iCAD, inc from 2002-2019.

Prior to the Covid pandemic, Dr. Brem was the Director of the George Washington University Mobile Mammography program (Mammovan), a mobile van that brings mammography to underserved communities to optimize the care of all women.

Dr. Brem was part of the formation of the Brem Foundation to Defeat Breast Cancer in 2004 with a group of committed patients and friends who have worked diligently to support risk based breast cancer screening as well as education and clinical care in the underserved community. The Brem Foundation was instrumental in passing dense breast legislation in the District of Columbia which has the highest death rate from cancer nationally.

 

 picture

Mark Koeniguer

CEO

Mark Koeniguer has over 25 years of healthcare industry experience launching innovative products and leading high-performance teams in domestic and international markets. He has been instrumental in launching and scaling many industry-first technologies including the first Computer Aided Detection algorithm for the early detection of breast cancer, the first mammography analytics platform and a multi-point risk stratified breast screening scorecard.

Prior to his serial entrepreneurial ventures, Mark held various executive leadership positions in Finance, Operations, Sales and Marketing for GE Healthcare. He holds a finance degree from the University of Iowa, and an MBA from the University of Wisconsin, Madison. 

 picture

Nico Karssemeijer

CSO

Professor Nico Karssemeijer is a leading scientist in breast cancer imaging and has been one of the pioneers of computer-aided detection, playing a key role in its development and adoptation in breast cancer screening. He was closely involved in the development of the R2 ImageChecker, the first mammography CAD product. He also played an important role in implementing digital mammography in the European screening programs, by initiating and leading EU funded projects in which breast screening workstations were developed that are marketed today by major vendors. He is a Professor in the Department of Radiology, Radboud University, Nijmegen, The Netherlands, and he is co-founder of Matakina Ltd and of QView Medical Inc.

 picture

Pieter Kroese

COO

Pieter Kroese has extensive international experience in general, commercial and financial management, and has always been intensively involved in strategy development. He has a background in various industries, leading organisations of up to 400 people. He also developed hands-on entrepreneurial experience as co-founder of a technical startup company. During the last 7 years, Pieter has primarily been working with software development companies. He joined ScreenPoint in 2018 and is responsible for all business activities, driving the commercial focus and growth of the company, as well as assuming responsibility for operations and finance.

 picture

Albert Gubern-Mérida

CTO

Dr. Gubern-Mérida obtained his joint Ph.D. degree in the field of medical imaging at the Diagnostic Image Analysis Group (DIAG) of the Radboud University Medical Center (Nijmegen, the Netherlands) and the University of Girona (Girona, Spain). His research focused on automated analysis of breast MRI, by developing image analysis and machine learning algorithms for breast cancer detection. As a post-doctoral researcher at DIAG, he expanded his research interest to other breast imaging modalities (mammography, digital breast tomosynthesis, and automated 3D breast ultrasound). In 2016, Dr. Gubern-Mérida joined ScreenPoint Medical, where he is currently the CTO, leading the continuous evolution of the AI technology within the company.

Join our team

ScreenPoint Medical is a fast growing scale up breast AI company which is continually looking for the best talent to strengthen all our teams to help us bring AI to the fight against breast cancer. If you share our passion, why not send us your resume and motivation letter?


MLOps Engineer

Imagine yourself working at a company that improves breast cancer survival rates. ScreenPoint is a rapidly growing company that develops


Senior AI Research Engineer

Imagine yourself working at a company that improves breast cancer survival rates. ScreenPoint is a rapidly growing company that develops


Software Support Engineer

About us ScreenPoint is a leading company that develops and markets breast image analysis and cutting edge machine learning applications


Our Partners

We are proud to work with some of the world’s leading organizations.

Transpara is a multi vendor solution and is compatible with most 2D and 3D mammography and PACS vendors.

News

Announcement


Transpara breast AI; strong clinical evidence evolves into real life screening use

Safely reducing radiologists’ workload for 2D and 3D mammography screening The Transpara AI breast care solution, now being used in

Read more

Publication


Transpara® breast AI reduces false positives and radiologists’ workload in largest Danish screening programme

The team running the country’s largest breast screening programme have shown that using Transpara breast AI further confirmed the enormous

Read more

Publication


The largest breast AI study to date shows value of Transpara in mammographic screening

In a recent study, the Cancer Registry of Norway used over 120,000 screening examinations from a population-based program to assess potential

Read more

Announcement


ScreenPoint Medical appoints new CEO

Following the success of the world’s leading AI Breast Care system, Transpara®, now in use across the US and in

Read more

Publication


A study with over 2,000 cancers missed by screening shows that Transpara AI can effectively help detect breast cancer earlier

ScreenPoint Medical’s Transpara AI decision support system can help radiologists to identify potential breast cancers earlier and faster, according to

Read more

Announcement


Transpara AI Breast Care – Global Expansion planned for 2022

Following the success of the world’s leading AI Breast Care system, Transpara®, now in use across the US and in

Read more